107 related articles for article (PubMed ID: 9130735)
1. Medroxyprogesterone acetate with Zoladex for long-term treatment of fibroids: effects on bone density and patient acceptability.
Caird LE; West CP; Lumsden MA; Hannan WJ; Gow SM
Hum Reprod; 1997 Mar; 12(3):436-40. PubMed ID: 9130735
[TBL] [Abstract][Full Text] [Related]
2. Goserelin acetate 10.8 mg plus iron versus iron monotherapy prior to surgery in premenopausal women with iron-deficiency anemia due to uterine leiomyomas: results from a Phase III, randomized, multicenter, double-blind, controlled trial.
Muneyyirci-Delale O; Richard-Davis G; Morris T; Armstrong J
Clin Ther; 2007 Aug; 29(8):1682-91. PubMed ID: 17919549
[TBL] [Abstract][Full Text] [Related]
3. Potential role for medroxyprogesterone acetate as an adjunct to goserelin (Zoladex) in the medical management of uterine fibroids.
West CP; Lumsden MA; Hillier H; Sweeting V; Baird DT
Hum Reprod; 1992 Mar; 7(3):328-32. PubMed ID: 1534089
[TBL] [Abstract][Full Text] [Related]
4. Estriol add-back therapy in the long-acting gonadotropin-releasing hormone agonist treatment of uterine leiomyomata.
Nakayama H; Yano T; Sagara Y; Kikuchi A; Ando K; Wang Y; Watanabe M; Matsumi H; Osuga Y; Momoeda M; Taketani Y
Gynecol Endocrinol; 1999 Dec; 13(6):382-9. PubMed ID: 10685331
[TBL] [Abstract][Full Text] [Related]
5. Bone metabolism in postmenopausal women who were treated with a gonadotropin-releasing hormone agonist and tibolone.
Palomba S; Morelli M; Di Carlo C; Noia R; Pellicano M; Zullo F
Fertil Steril; 2002 Jul; 78(1):63-8. PubMed ID: 12095492
[TBL] [Abstract][Full Text] [Related]
6. [Effect of GnRH analogues on bone density in the vertebral column and the femur].
Perrone G; Galoppi P; Critelli C; Bazzoffi R; Capri O; Barillaro F; Zichella L
Minerva Ginecol; 1995 Oct; 47(10):461-5. PubMed ID: 8559437
[TBL] [Abstract][Full Text] [Related]
7. Long-term effectiveness and safety of GnRH agonist plus raloxifene administration in women with uterine leiomyomas.
Palomba S; Orio F; Russo T; Falbo A; Cascella T; Doldo P; Nappi C; Lombardi G; Mastrantonio P; Zullo F
Hum Reprod; 2004 Jun; 19(6):1308-14. PubMed ID: 15117890
[TBL] [Abstract][Full Text] [Related]
8. Efficacy of tibolone as "add-back therapy" in conjunction with a gonadotropin-releasing hormone analogue in the treatment of uterine fibroids.
Morris EP; Rymer J; Robinson J; Fogelman I
Fertil Steril; 2008 Feb; 89(2):421-8. PubMed ID: 17572410
[TBL] [Abstract][Full Text] [Related]
9. The place of Zoladex in deferred surgery for uterine fibroids. Zoladex Myoma Study Group.
Gerris J; Degueldre M; Peters AA; Romao F; Stjernquist M; al-Taher H
Horm Res; 1996; 45(6):279-84. PubMed ID: 8793522
[TBL] [Abstract][Full Text] [Related]
10. Maintained reduction of uterine leiomyoma following addition of hormonal replacement therapy to a monthly luteinizing hormone-releasing hormone agonist implant: a pilot study.
Maheux R; Lemay A; Blanchet P; Friede J; Pratt X
Hum Reprod; 1991 Apr; 6(4):500-5. PubMed ID: 1655823
[TBL] [Abstract][Full Text] [Related]
11. The effect of combined androgen blockade on bone turnover and bone mineral densities in men treated for prostate carcinoma: longitudinal evaluation and response to intermittent cyclic etidronate therapy.
Diamond T; Campbell J; Bryant C; Lynch W
Cancer; 1998 Oct; 83(8):1561-6. PubMed ID: 9781950
[TBL] [Abstract][Full Text] [Related]
12. Adjuvant endocrine therapy plus zoledronic acid in premenopausal women with early-stage breast cancer: 5-year follow-up of the ABCSG-12 bone-mineral density substudy.
Gnant M; Mlineritsch B; Luschin-Ebengreuth G; Kainberger F; Kässmann H; Piswanger-Sölkner JC; Seifert M; Ploner F; Menzel C; Dubsky P; Fitzal F; Bjelic-Radisic V; Steger G; Greil R; Marth C; Kubista E; Samonigg H; Wohlmuth P; Mittlböck M; Jakesz R;
Lancet Oncol; 2008 Sep; 9(9):840-9. PubMed ID: 18718815
[TBL] [Abstract][Full Text] [Related]
13. Long-term treatment of uterine fibroids with ulipristal acetate ☆.
Donnez J; Vázquez F; Tomaszewski J; Nouri K; Bouchard P; Fauser BC; Barlow DH; Palacios S; Donnez O; Bestel E; Osterloh I; Loumaye E;
Fertil Steril; 2014 Jun; 101(6):1565-73.e1-18. PubMed ID: 24630081
[TBL] [Abstract][Full Text] [Related]
14. Bone mineral density in premenopausal women treated for node-positive early breast cancer with 2 years of goserelin or 6 months of cyclophosphamide, methotrexate and 5-fluorouracil (CMF).
Fogelman I; Blake GM; Blamey R; Palmer M; Sauerbrei W; Schumacher M; Serin D; Stewart A; Wilpshaar W
Osteoporos Int; 2003 Dec; 14(12):1001-6. PubMed ID: 14530912
[TBL] [Abstract][Full Text] [Related]
15. [The effects of menopausal replacement therapy in women with uterine myomas].
Orsini G; Pinto V; Di Biase S; D'Altorio C; Lanzilotti G
Minerva Ginecol; 1999 Nov; 51(11):421-5. PubMed ID: 10726441
[TBL] [Abstract][Full Text] [Related]
16. An evaluation of the effect of gonadotropin-releasing hormone analogs and medroxyprogesterone acetate on uterine leiomyomata volume by magnetic resonance imaging: a prospective, randomized, double blind, placebo-controlled, crossover trial.
Carr BR; Marshburn PB; Weatherall PT; Bradshaw KD; Breslau NA; Byrd W; Roark M; Steinkampf MP
J Clin Endocrinol Metab; 1993 May; 76(5):1217-23. PubMed ID: 8496313
[TBL] [Abstract][Full Text] [Related]
17. Long-term medical therapy for leiomyomata uteri: a prospective, randomized study of leuprolide acetate depot plus either oestrogen-progestin or progestin 'add-back' for 2 years.
Friedman AJ; Daly M; Juneau-Norcross M; Gleason R; Rein MS; LeBoff M
Hum Reprod; 1994 Sep; 9(9):1618-25. PubMed ID: 7836510
[TBL] [Abstract][Full Text] [Related]
18. Change in C-terminal cross-linking domain of type I collagen in urine, a new marker of bone resorption, during and after gonadotropin-releasing hormone agonist administration.
Taga M; Minaguchi H
Eur J Endocrinol; 1997 Aug; 137(2):167-71. PubMed ID: 9272105
[TBL] [Abstract][Full Text] [Related]
19. Long-term administration of tibolone plus gonadotropin-releasing hormone agonist for the treatment of uterine leiomyomas: effectiveness and effects on vasomotor symptoms, bone mass, and lipid profiles.
Palomba S; Affinito P; Di Carlo C; Bifulco G; Nappi C
Fertil Steril; 1999 Nov; 72(5):889-95. PubMed ID: 10560995
[TBL] [Abstract][Full Text] [Related]
20. Effects on bone mineral density of 12-month goserelin treatment in over 40-year-old women with uterine myomas.
Bianchi S; Fedele L; Vignali M; Galbiati E; Cherubini R; Ortolani S
Calcif Tissue Int; 1995 Jul; 57(1):78-80. PubMed ID: 7671171
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
